Serial Changes of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Levels in Patients With Acute Respiratory Distress Syndrome

Serial Changes of sTREM-1 Levels in Patients With Acute Respiratory Distress Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00557414

Enrollment

Registered

2007-11-14

Start date

2007-10-31

Completion date

2008-03-31

Last updated

2008-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Keywords

acute respiratory distress syndrome, soluble triggering receptor expressed on myeloid cells-1, prognosis

Brief summary

The purpose of this study is to determine the impact of the serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) on etiology and prognosis of acute respiratory distress syndrome (ARDS)

Detailed description

The triggering receptor expressed on myeloid cells-1 (TREM-1), a member of the immunoglobulin superfamily, is upregulated on phagocytic cells in the presence of bacteria or fungi infection and weakly expressed in samples from patients with noninfectious inflammatory disorders. In addition, TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form (sTREM-1) in body fluids. The level and serial change of a serum sTREM-1 from cirtical ill patients has been shown to be a good diagnostic and prognostic indicator of ventilation associated pneumonia (VAP) and severe sepsis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Fulfill clinical diagnosis of ARDS * Require mechanical ventilation support

Exclusion criteria

* Pregnant * Immunocompromised

Design outcomes

Primary

Measure	Time frame
all cause mortality	28 days
Septic or non-septic etiology	At enrollment

Secondary

Measure	Time frame
CRP, lactate, WBC count, APACHE II score, LIS, SOFA score	At enrollment
IL-1 beta, IL-8, TNF-alpha	serial follow up at Day 1, 3, 5, 7, 14

Countries

Taiwan

Outcome results